Patents by Inventor Jeyaraj Antony

Jeyaraj Antony has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20240002796
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: January 17, 2023
    Publication date: January 4, 2024
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • NUCLEIC ACIDS ENCODING ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20220152112
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Applicant: Precision BioSciences, Inc.
    Inventors: Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20220135945
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 5, 2022
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 11268065
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: March 8, 2022
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
    Patent number: 11266693
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: March 8, 2022
    Assignee: Precision BioSciences, Inc.
    Inventors: Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20210207093
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: March 1, 2021
    Publication date: July 8, 2021
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20210052650
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.
    Type: Application
    Filed: September 9, 2020
    Publication date: February 25, 2021
    Applicant: Precision BioSciences, Inc.
    Inventors: Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
  • Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
    Patent number: 10799535
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: October 13, 2020
    Assignee: Precision BioSciences, Inc.
    Inventors: Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20190194616
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: October 2, 2018
    Publication date: June 27, 2019
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180289741
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 11, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 10093900
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 9, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 10093899
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 9, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180265845
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 20, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180258392
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 13, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9993501
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 12, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9993502
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 12, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180140635
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 24, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180133254
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 17, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9969975
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: May 15, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9950011
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 24, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich